Efficacy of multidisciplinary treatment program on long-term outcomes of individuals with Parkinson's disease

被引:32
作者
Carne, William
Cifu, David X.
Marcinko, Paul
Baron, Mark
Pickett, Treven
Qutubuddin, Abu
Calabrese, Vincent
Roberge, Peggy
Holloway, Kathryn
Mutchler, Brian
机构
[1] PADRECC, Dept Rehabil Med, Hunter Holmes McGuire VAMC, Richmond, VA 23249 USA
[2] VAMC, Hunter Holmes McGuire Dept, SE Parkinsons Dis Res Educ & Clin Ctr, Richmond, VA USA
[3] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23284 USA
[4] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23284 USA
[5] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23284 USA
关键词
disease progression; intervention; levodopa; Movement disorder; multidisciplinary team; neurology; outcomes; Parkinson's disease; rehabilitation; Unified Parkinson's Disease Rating Scale;
D O I
10.1682/JRRD.2005.03.0054
中图分类号
R49 [康复医学];
学科分类号
100215 ;
摘要
We examined the impact of multidisciplinary clinical management of the Parkinson's Disease Research, Education, and Clinical Center program on Parkinson's disease progression. Initial and follow-up scores on the Part III Motor Examination subscale of the Unified Parkinson's Disease Rating Scale (UPDRS) were examined. Overall, 37 (75.5%) of the 49 patients demonstrated stable or improved UPDRS motor scores at 1- to 3-year follow-up; in the 1-year group (n = 28), 22 patients (78.6%) improved, while 6 (21.4%) worsened. In the 2-year group (n = 15). 10 (66.7%) improved, while 5 (33.3%) worsened. In the 3-year group (n = 6), 5 (83.3%) improved, while 1 (16.7%) worsened. Multidisciplinary interventions included neurology (95.9% of patients), physiatry (93.9%). nursing (87.8%), psychology (42.9%), medication changes (59.2% increases, 18.4% decreases), rehabilitation therapies (physical, occupational, speech-language, 67.3%), functional diagnostic testing (18.4%), support group (16.3%), home exercise instruction (85.7%), and disease and wellness education (81.6%). Improved and worsened patients did not significantly differ on the individual program components. Clinical implications and study limitations are discussed.
引用
收藏
页码:779 / 786
页数:8
相关论文
共 37 条
  • [1] Ropinirole for the treatment of early Parkinson's disease
    Adler, CH
    Sethi, KD
    Hauser, RA
    Davis, TL
    Hammerstad, JP
    Bertoni, J
    Taylor, RL
    SanchezRamos, J
    OBrien, CF
    [J]. NEUROLOGY, 1997, 49 (02) : 393 - 399
  • [2] Slowing Parkinson's disease progression - Recent dopamine agonist trials
    Ahlskog, JE
    [J]. NEUROLOGY, 2003, 60 (03) : 381 - 389
  • [3] A RANDOMIZED, CONTROLLED TRIAL OF A GERIATRIC ASSESSMENT UNIT IN A COMMUNITY REHABILITATION HOSPITAL
    APPLEGATE, WB
    MILLER, ST
    GRANEY, MJ
    ELAM, JT
    BURNS, R
    AKINS, DE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (22) : 1572 - 1578
  • [4] Cameron IT, 2005, COMPUT-AIDED CHEM EN, V20a-20b, P3
  • [5] Drug treatment effects on disease progression
    Chan, PLS
    Holford, NHG
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 : 625 - 659
  • [6] Choudhury SR, 2001, J REHABIL RES DEV, V38, P293
  • [7] Factors affecting functional outcome after stroke: A critical review of rehabilitation interventions
    Cifu, DX
    Stewart, DG
    [J]. ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 1999, 80 (05): : S35 - S39
  • [8] Fahn S, 2004, NEW ENGL J MED, V351, P2498
  • [9] Parkinson disease, the effect of levodopa, and the ELLDOPA trial
    Fahn, S
    [J]. ARCHIVES OF NEUROLOGY, 1999, 56 (05) : 529 - 535
  • [10] CONSIDERATIONS IN MANAGEMENT OF PARKINSONISM
    FAHN, S
    CALNE, DB
    [J]. NEUROLOGY, 1978, 28 (01) : 5 - 7